REG - ValiRx PLC - Directorate Change

ValiRxAnnouncement

18/10/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241018:nRSR6828Ia&default-theme=true

RNS Number : 6828I  ValiRx PLC  18 October 2024

ValiRx plc

 

("ValiRx" or the "Company")

 

Directorate Change

 

ValiRx plc (AIM: VAL), a life sciences company focusing on early-stage cancer
therapeutics and women's health, announces the resignation of Martin Lampshire
as a Non-Executive Director of the Company, effective from 18 October 2024.

 

Martin has decided to step down from the Board of ValiRx to concentrate on his
other commitments.

 

During Martin's four year tenure as a ValiRx Non-Executive Director, he has
made significant contributions to the development of the strategy and helped
the Company build relationships with various City stakeholders.

 

Martin Gouldstone, Chairman of ValiRx commented "I would very much like to
extend my sincere appreciation to Martin for his contributions whilst serving
as Non Executive Director for ValiRx. He has been a great support of the
Company during the short time that both myself and Mark Eccleston have been in
our respective roles and has helped with identifying further cost reductions
that ValiRx can make in the short term to allow us to concentrate on the
Company's longer term commercial and strategic objectives."

 

Mark Eccleston, CEO of ValiRx commented " I too would like to thank Martin for
his contribution and guidance in my limited tenure to date. As ValiRx moves
forward the board will evolve to bring more commercial and clinical
development experience which, alongside cost savings in the range of  £100,
000 we have identified, will focus the Company on building its therapeutic
pipeline."

 

The Directors of the Company take responsibility for this announcement.

For more information, please contact:

 

 ValiRx plc                                        Tel: +44 (0) 115 784 0026

                                                   www.valirx.com

 Dr Mark Eccleston, CEO                            info@valirx.com (mailto:mark.eccleston@valirx.com)

 V Formation (Public Relations)                    +44 (0) 115 787 0206

                                                   www.vformation.biz (http://www.vformation.biz/)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                               lucy@vformation.biz

                                                   sue@vformation.biz
 Cairn Financial Advisers LLP (Nominated Adviser)  Tel: +44 (0) 20 7213 0880

 Liam Murray/Ludovico Lazzaretti

 Shard Capital Partners LLP (Sole Broker)          Tel: +44 (0) 20 7186 9000

 Damon Heath

 BioRep srl                                        Tel: +39 335 665 6824

 Daniela Sica (BU Biotech CCO)

 Sapio Group                                       Tel: +39 039 839 8242

 Valentina Semeraro (Head of Media Relations)

 

 

Notes for Editors

 

About ValiRx

 

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com (http://www.valirx.com/)

 

Cautionary statement

Certain statements made in this announcement are forward-looking statements.
Such statements are based on current expectations and assumptions and are
subject to a number of risks and uncertainties that could cause actual events
or results to differ materially from any expected future events or results
expressed or implied in these forward-looking statements. Persons receiving
this announcement should not place undue reliance on forward-looking
statements. Unless otherwise required by applicable law, regulation or
accounting standard, the Company does not undertake to update or revise any
forward-looking statements, whether as a result of new information, future
developments or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAGPGCCUUPCPUM